Printed from Voxsanity (voxsanity.com.au) — NCT07115446 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Prostate Cancer
Phase 1 Prostate Cancer Trial, Recruiting
NCT07115446
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 years or older
- People who are willing to take part and have signed and dated a consent form
- People who have prostate cancer that has spread to other parts of the body, is no longer responding to hormone-lowering treatments (called castration-resistant), and has continued to grow after at least one standard hormone-based treatment
- People whose general health and ability to carry out daily activities meets a specific level of fitness, rated 0 or 1 on a standard medical scale (confirm with trial site)
- People whose doctors estimate they have a life expectancy of at least 12 weeks
- Men who are willing and able to use adequate contraception throughout the study and for up to 3 months after the last dose of one study drug (HRS-5041) or 4.5 months after the last dose of the other study drug (HS-20093), whichever is later
Who may not be able to join:
- People who have previously received or are currently receiving a treatment that targets a protein called B7-H3
- People who have previously received a type of treatment called AR PROTAC (confirm with trial site)
- People who have received certain cancer treatments — including chemotherapy, experimental drugs, or other anticancer medicines — within 21 days before the first planned dose of the study drugs
- People whose cancer has spread to the brain
- People who still have significant unresolved side effects from a previous cancer treatment
- People who have a history of another primary cancer (a separate, unrelated cancer)
- People whose bone marrow, liver, kidneys, or other organs are not working well enough (confirm with trial site)
- People with serious, uncontrolled, or active heart or blood vessel disease
- People with severe or poorly controlled diabetes
- People with an active infection at the time of joining
- People with a known or suspected lung condition called interstitial lung disease
- People with a history of serious nerve damage or mental health disorders
- People who have previously had a severe allergic reaction or a severe reaction to an infusion (drip) treatment
- People who are allergic to any ingredient in the study drug HS-20093
- People who, in the treating doctor's opinion, are unlikely to follow the study procedures and requirements
- People who have any other condition that, in the treating doctor's opinion, could affect their safety or interfere with the study results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Hansoh BioMedical R&D Company
Registry
ClinicalTrials.gov
Start date
19 August 2025
Est. completion
1 December 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
To determine the maximum tolerated dose (MTD) or Maximum Administrated dose (MAD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.